Search

Displaying results 721 - 730 of 4300 in total
  1. Drug

    SSR-126517E

    go.drugbank.com/drugs/DB05362
    Experimental

    SSR-126517E is a second generation synthetic pentasaccharide that binds antithrombin with such high affinity that it assumes a plasma half-life of 80 hours.

  2. Drug

    Docusate

    go.drugbank.com/drugs/DB11089
    Approved

    Still docusate is available in over-the-counter products as a common laxative. … Docusate acts by increasing the amount of water the stool absorbs in the gut, making the stool softer and easier to pass [L1801]. Docusate can be orally or rectally administered.

  3. Drug

    Anakinra

    go.drugbank.com/drugs/DB00026
    ApprovedInvestigational

    On November 14, 2001, it was approved by the FDA for the treatment of rheumatoid arthritis.

  4. Drug

    Ofatumumab

    go.drugbank.com/drugs/DB06650
    ApprovedInvestigational

    [A6921] Ofatumumab is available for intravenous administration and is marketed as Arzerra. … [A6921] Ofatumumab was first approved by the FDA in 2009.

  5. Drug

    Sulbactam

    go.drugbank.com/drugs/DB09324
    ApprovedInvestigational

    [L50131] When given in combination with β-lactam antibiotics, sulbactam produces a synergistic effect as it blocks the enzyme responsible for drug resistance by hydrolyzing β-lactams.[A263296]

  6. Drug

    Crotalus adamanteus antivenin

    go.drugbank.com/drugs/DB13893
    Approved

    The final purified antivenin product is obtained by mixing other different monospecific snake antivenins and isolating the antivenin of interest through fractionation and chromatography techniques.

  7. Drug

    Zotepine

    go.drugbank.com/drugs/DB09225
    ApprovedWithdrawn

    In 1993, it was classified as inactive drug substance (Status I, Type II) and in 1995 the FDA studied the manufacturing procedures of Zotepine tablets in Germany, but the status remained inactive. … [A31857] Zotepine was never approved by the FDA.

  8. Drug

    Olutasidenib

    go.drugbank.com/drugs/DB16267
    ApprovedInvestigational

    Olutasidenib (FT-2102) is a selective and potent isocitrate dehydrogenase-1 (IDH1) inhibitor approved by the FDA in December 2022. … [L44256,L44261] It is indicated for the treatment of relapsed or refractory acute myeloid leukemia (AML) in patients with a susceptible IDH1 mutation as determined by an FDA-approved test.

  9. Drug

    Pentobarbital

    go.drugbank.com/drugs/DB00312
    ApprovedVet approved

    It is prescribed more frequently for sleep induction than for sedation but, like similar agents, may lose its effectiveness by the second week of continued administration. … A short-acting barbiturate that is effective as a sedative and hypnotic (but not as an anti-anxiety) agent and is usually given orally.

  10. Drug

    Insulin human

    go.drugbank.com/drugs/DB00030
    ApprovedInvestigational

    Exubera was the first inhaled insulin available on the market and was developed by Inhale Therapeutics (later named Nektar Therapeutics). … Human insulin is also available in an inhalable form, intended to be used as a bolus meal-time insulin.